The Headlines
In 2017 Dechra delivered 20 years of growth through our strategic growth drivers Portfolio Focus, Pipeline Delivery, Geographic Expansion and Acquisition.
Our total revenue of £359.3m in 2017 represents a 45.1% growth on the previous year (at Actual Exchange rate) and 28.3% growth (at Constant Exchange Rate).
What we do best
Our key areas of expertise span endocrinology, dermatology, cardiology, water soluble powder products and injectable antibiotics, anaesthetics and analgesics, equine medicine and diet and nutrition. Our major products include:
- Vetoryl® Capsules, for the treatment of canine hyperadrenocorticism (Cushing's syndrome)
- Dermatology brands Canaural®, Isaderm® Gel and Malaseb® Shampoo
- Felimazole® Tablets, for treating feline hyperthyroidism
- Added value pharmaceuticals - Cardisure® and Forthyron®, for treating canine congestive heart disease and hypothyroidism respectively
- Cyclospray® an antibiotic spray for treating claw / hoof problems like Mortallaro’s disease in cattle and superficial wounds
- Soludox 50% and Octacillin® for treating respiratory and enteric disease in pigs and poultry
- Equipalazone®, the anti-inflammatory and analgesic for equine musculoskeletal disorders
- SPECIFIC™, a complete, vet exclusive premium diet range that provides precise nutritional solutions throughout the lives of cats and dogs.
Navigation